Crystal form of Dabrafenib and preparation method of use thereof
US9365559B2 · kind B2 · utility
0Cited by
1References
15Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 8, 2015 |
| Grant date | Jun 14, 2016 |
| Priority date | — |
| Expiry date | Jul 8, 2035 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07B2200/13
- WIPO fieldSurface technology, coating
- WIPO sectorChemistry
Abstract
The invention relates to Crystal Hydrate Form VI of Dabrafenib and preparation method thereof, wherein Crystal Hydrate Form VI of Dabrafenib has the advantage of being more stable at room temperature or in aqueous systems, and has low hygroscopicity, and thus is more suitable for a wet granulation process or being prepared into a suspension; and the present invention also relates to a pharmaceutical composition and formulations comprising Crystal Hydrate Form VI of Dabrafenib, and their use in the treatment of Raf family kinase-related diseases.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.